Intensity Therapeutics

Q2 FY2026 EarningsQ2 FY2026 results missed consensus on the bottom line, with a GAAP EPS loss of -$1.11 vs. -$0.97 expected. Revenue remained at $0, consistent with its stage as a clinical-biotech firm. Operating loss of -$3.08M was primarily driven by the resumption of the Phase 3 INVINCIBLE-3 study and higher administrative costs following the February 2026 reverse stock split. Cash reserves of $9.5M, supplemented by $1.3M in post-quarter ATM proceeds, remain thin, leading to a continued 'going concern' warning as the company seeks substantial additional funding for Phase 3 trials.